Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Shares (2020 - 2025)

Viridian Therapeutics, Inc.\DE has reported Preferred Shares over the past 6 years, most recently at $70.9 million for Q4 2025.

  • Quarterly results put Preferred Shares at $70.9 million for Q4 2025, down 44.5% from a year ago — trailing twelve months through Dec 2025 was $70.9 million (down 44.5% YoY), and the annual figure for FY2025 was $70.9 million, down 44.5%.
  • Preferred Shares for Q4 2025 was $70.9 million at Viridian Therapeutics, Inc.\DE, up from $61.2 million in the prior quarter.
  • Over the last five years, Preferred Shares for VRDN hit a ceiling of $145.8 million in Q3 2021 and a floor of $15.7 million in Q2 2022.
  • Median Preferred Shares over the past 5 years was $74.8 million (2023), compared with a mean of $86.0 million.
  • Biggest five-year swings in Preferred Shares: plummeted 61.13% in 2022 and later soared 261.71% in 2023.
  • Viridian Therapeutics, Inc.\DE's Preferred Shares stood at $118.2 million in 2021, then fell by 27.67% to $85.5 million in 2022, then soared by 50.09% to $128.3 million in 2023, then decreased by 0.46% to $127.7 million in 2024, then plummeted by 44.5% to $70.9 million in 2025.
  • The last three reported values for Preferred Shares were $70.9 million (Q4 2025), $61.2 million (Q3 2025), and $61.2 million (Q2 2025) per Business Quant data.